

In response to the Office Action of February 12, 2003, please amend the application as follows:

5 IN THE CLAIMS

✓ Please cancel claims 1-14, 26, and 27 without prejudice or disclaimer.

✓ Please add new claims 29-44, inclusive, as follows:

10 --29. A complex of paroxetine, as a free base or as a salt, with a cyclodextrin or with a cyclodextrin derivative.

30. The complex as claimed in claim 29, wherein it is in the form of a flowing powder, it has a greater stability in comparison with the non-complexed paroxetine, organic solvents are absent, it has a higher solubility in water with respect to the non-complexed paroxetine and a DSC profile different from that of
15 the corresponding non-complexed paroxetine or paroxetine salt.

31. The complex as claimed in claim 30, wherein ethanol is absent.

32. The complex as claimed in claim 29, having a water content of between 1 and 20%, by weight.

20 33. The complex as claimed in claim 32, wherein water content is between 2 and 15%, by weight.

34. The complex as claimed in claim 29, wherein the cyclodextrin is selected from the group consisting of α , β and γ -cyclodextrin.

35. The complex as claimed in claim 34, wherein the cyclodextrin is a β -cyclodextrin.

25 36. The complex as claimed in claim 29, wherein the cyclodextrin derivative is selected from the group consisting of heptakis (2,6-di-O-methyl)- β -cyclodextrin, heptakis (2,3,6-tri-O-methyl)- β -cyclodextrin, monosuccinyl-heptakis(2,6-di-O-methyl)- β -cyclodextrin, 2-hydroxypropyl- β -cyclodextrin, sulphated cyclodextrin and cyclodextrin containing aminoalkyl groups.

30 37. The complex as claimed in claim 36, wherein the cyclodextrin derivative is the 2-hydroxypropyl- β -cyclodextrin.

38. The complex as claimed in claim 29, wherein the salt of paroxetine